Scottish Marine Biotech Firm and China Firm Link Up

Posted On: May 11, 2009

Oban-based GlycoMar and Glasgow-based Scottish Biomedical have signed agreements with Chinese pharmaceutical giant Asiapharm to test and potentially license two of their lead products. The GlycoMar products have potential for the treatment of cardiovascular disease, while the Scottish Biomedical drugs could treat debilitating psychotic disorders such as schizophrenia. Scotland’s life sciences industry is one of the most vibrant in Europe – with about 600 organizations employing over 30,000 people. Under the terms of the deal, Asiapharm will carry out trials and further development of the two products. If successful, Asiapharm will license these products for the Chinese market.

More Info